Insulet Corp
Closed
SectorHealthcare
137.83 4.57
Overview
Share price change
24h
Min
131.56
Max
132.88
Income | 3.9M 95M |
|---|---|
Sales | 40M 802M |
P/E Sector Avg | 27.618 56.597 |
EPS | 1.66 |
Profit margin | 11.85 |
Employees | 5,400 |
EBITDA | -22M 132M |
Next Earnings | 5 Nov 2026 |
|---|
Market Cap | -1.5B 10B |
|---|---|
Previous open | 133.26 |
Previous close | 137.83 |
News Sentiment
By Acuity
64%
36%
287 / 339 Healthcare
Insulet Corp Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Insulet Corp Forecast
Sentiment
By Acuity
287 / 339 Healthcare
News Sentiment
Bearish Evidence
Volatility
Below average
News Volume (RCV)
Above average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Insulet Corp
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.